ARCHIVES

Supreme Court Decision Means FTC Scrutiny As Costly Oncology Drugs Go Off-Patent

This article is from The Cancer Letter archive.

Vol. 39 No. 25 | June 21, 2013

Download PDF Visit The Full Archive

Related Articles

Docetaxel, Oxaliplatin Active Against Esophageal Cancer

June 30, 2006

Iressa May Benefit Some Breast Cancer, Studies Find

December 27, 2002

Dingell: “Unable To Vouch” For Staff Report On NCI’s Gallo

February 10, 1995

NSAIDs Cut Oral Cancer Risk But Raise Smokers’ Heart Risk

October 28, 2005

Tamoxifen Listed By IARC Report As Carcinogen CTRF Seeks Applicants

March 1, 1996

Funding Opportunities

October 4, 2002